Association of remnant cholesterol with kidney outcomes in adults with type 2 diabetes: a systematic review and meta-analysis

Scientists poring over data from nearly three million adults with type 2 diabetes have found that a little-known blood fat measure may flag kidney trouble long before conventional cholesterol tests do. The measure, called remnant cholesterol, captures the cholesterol carried by triglyceride-rich lipoprotein remnants — the sticky, partially degraded particles left behind after the body clears dietary and liver-derived fats from the bloodstream. According to a systematic review and meta-analysis published in Frontiers in Endocrinology, adults with type 2 diabetes who carry higher levels of this remnant burden face a substantially elevated risk of developing diabetic kidney disease, the leading cause of kidney failure worldwide.

The research team, led by Jie Gao of Yan’an University and colleagues from Xi’an Jiaotong University, followed the PRISMA 2020 reporting framework and registered their protocol in PROSPERO before screening 1,078 records from PubMed/MEDLINE, Scopus, the Cochrane Library, Google Scholar, Wiley Online Library, and ScienceDirect. After removing duplicates and excluding reports that lacked separately extractable type 2 diabetes data or eligible adjusted effect estimates, seventeen articles survived, contributing eighteen independent estimates from 2,817,820 participants across China, Japan, South Korea, the United Kingdom, and the United States. Eleven studies were longitudinal cohorts tracking kidney outcomes over time, while six were cross-sectional investigations assessing kidney status at a single point.

The pooled numbers are striking. An exploratory model combining all studies showed that higher remnant cholesterol was associated with adverse kidney outcomes overall, with an association ratio of 1.50 (95% CI 1.32–1.72, P < 0.001), although heterogeneity was high at 87.6%, reflecting the mixture of designs, outcomes, and exposure contrasts. When the analysis was restricted to the twelve longitudinal estimates from eleven articles, the association remained robust: adults with higher remnant cholesterol had a 27% higher hazard of adverse kidney outcomes (HR 1.27, 95% CI 1.17–1.37, P < 0.001), with heterogeneity dropping to a more reassuring 42.9%. Leave-one-out sensitivity analyses confirmed that no single study drove the result, with pooled hazard ratios ranging narrowly from 1.24 to 1.29.

Outcome-specific analyses sharpened the picture further. Across five independent cohorts from four articles, higher remnant cholesterol was associated with incident diabetic kidney disease — the onset of new kidney damage in people who had healthy kidneys at baseline — with a hazard ratio of 1.27 (95% CI 1.15–1.41, P = 0.0029) and remarkably low heterogeneity of just 7.4%. Restricting the analysis to the highest-quality studies scoring eight or nine stars on the Newcastle–Ottawa Scale produced a nearly identical estimate (HR 1.25, 95% CI 1.17–1.34, P = 0.0019, I² = 0%). One study also reported that higher remnant cholesterol predicted incident albuminuria, the leakage of protein into urine that marks early glomerular injury (HR 1.23, 95% CI 1.06–1.43, P = 0.007).

Not every kidney outcome reached statistical significance. The pooled estimate for kidney failure or end-stage kidney disease was positive but nonsignificant (HR 1.56, 95% CI 0.82–2.97, P = 0.115), burdened by substantial heterogeneity of 69.5% and only four contributing studies. The association with diabetic kidney disease progression — worsening damage in people who already had the condition — showed a positive trend that just missed the conventional threshold (HR 1.17, 95% CI 1.00–1.37, P = 0.052). These narrower analyses suggest that remnant cholesterol may be most informative for predicting the onset of diabetic kidney disease rather than its progression to kidney failure, though the limited number of studies for these rarer outcomes reduces confidence.

The cross-sectional evidence was even more dramatic. Across six studies, adults with type 2 diabetes and higher remnant cholesterol had roughly double the odds of prevalent or early diabetic kidney disease compared with those in the lowest remnant cholesterol category (OR 2.03, 95% CI 1.71–2.42, P < 0.001), with heterogeneity nearly absent at 2.5%. Because RC and kidney status were measured concurrently, this finding reflects a prevalence association rather than disease onset, but the tight clustering of estimates across diverse hospitalized and population-based cohorts lends weight to the observation.

Critically, the association survived aggressive statistical adjustment. When the team restricted the longitudinal analysis to estimates that had been adjusted for blood pressure, glycemia, and adiposity — the three cardiometabolic domains most likely to confound the relationship — the hazard ratio barely budged to 1.28 (95% CI 1.21–1.37, P < 0.001), with heterogeneity falling to 17.5%. Adding diabetes duration as a fourth required domain in a smaller subset of five articles produced a similar result (HR 1.24, 95% CI 1.12–1.37, P = 0.011). This suggests that remnant cholesterol captures kidney risk beyond what conventional metabolic measures explain.

Yet the dose–response picture is murkier. A smaller subset of three cohorts from two articles that reported continuous estimates found no statistically significant association per 0.1 mmol/L increase in remnant cholesterol (HR 1.02, 95% CI 0.98–1.07, P = 0.197), with high heterogeneity of 81.4%. An exploratory spline analysis reconstructed from the categorical data of five cohorts showed a significant overall association across the observed remnant cholesterol range (P = 0.0128), with predicted hazard ratios of 1.10, 1.19, and 1.26 at concentrations of 0.60, 0.80, and 1.00 mmol/L respectively, using 0.40 mmol/L as the reference. However, the test for nonlinearity was not significant (P = 0.340), meaning no distinct threshold or curved pattern emerged. The authors conclude that remnant cholesterol may serve as a complementary kidney-risk marker but that no common clinical threshold can be defined from the current evidence.

The biological plausibility runs deep. In type 2 diabetes, insulin resistance drives the liver to overproduce very-low-density lipoprotein while impairing lipoprotein lipase-mediated clearance, prolonging the circulation time of triglyceride-rich remnant particles and increasing their exposure to the glomerular endothelium. Experimental work shows that these remnants trigger redox-sensitive inflammatory chemokine expression in human vascular endothelial cells, and analyses of kidney tissue from patients with diabetic nephropathy have revealed marked lipid deposition, downregulated fatty acid oxidation and cholesterol efflux pathways, and upregulated lipid-uptake receptors alongside inflammatory and fibrotic genes. Remnant cholesterol also more directly represents the cholesterol burden carried by apolipoprotein B-containing remnant particles than triglycerides alone, and higher levels have been independently linked to ischemic heart disease, low-grade inflammation, and diabetic retinopathy — suggesting that diabetic microvascular complications may share common lipotoxic pathways.

The clinical implications are tantalizing but tempered. Remnant cholesterol can be calculated cheaply from routine lipid panels as total cholesterol minus HDL cholesterol minus LDL cholesterol, making it an accessible addition to kidney-risk assessment alongside eGFR and urinary albumin-to-creatinine ratio. Conventional lipid-lowering therapies have a modest effect on remnant levels — a meta-regression of statin, ezetimibe, and PCSK9 inhibitor trials found that each 1 mmol/L reduction in LDL cholesterol corresponded to only about 0.19 mmol/L reduction in remnant cholesterol — while emerging agents targeting apolipoprotein C-III or ANGPTL3 have cut remnant levels by 38% to 70% in early trials. Whether directly lowering remnant cholesterol protects the kidneys in type 2 diabetes remains unproven; the FIELD, ACCORD, and PROMINENT trials of triglyceride-modifying therapies reported inconsistent kidney and cardiovascular effects. The authors emphasize that all included evidence was observational, so residual confounding, reverse causation, and selective reporting cannot be excluded, and GRADE certainty was rated low for incident diabetic kidney disease and very low for the other outcomes. Most participants were from East Asia, limiting generalizability, and reporting of lipid-lowering therapies, SGLT2 inhibitors, GLP-1 receptor agonists, and renin–angiotensin system blockers varied across studies. The team calls for standardized remnant cholesterol measurement, consistent medication adjustment, and prospective trials that prespecify eGFR decline and albuminuria progression as kidney outcomes to determine whether this overlooked blood fat deserves a place in routine diabetes care.

Subject of Research: Association of remnant cholesterol with kidney outcomes in adults with type 2 diabetes: a systematic review and meta-analysis

Article Title: Association of remnant cholesterol with kidney outcomes in adults with type 2 diabetes: a systematic review and meta-analysis

Article References: Gao, J., Wang, J., & Wang, Z. (2026). Association of remnant cholesterol with kidney outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. Frontiers in Endocrinology, 17, Article 1969361. https://doi.org/10.3389/fendo.2026.1969361

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.1969361

Keywords: Association, remnant, cholesterol, kidney, outcomes, adults, type, diabetes, systematic, review, meta-analysis, scientific research